RxDoctor Payments DataLook up a doctor →

Ravi Patel, MD

Ophthalmology · Eatontown, NJNPI 1205038262

Payments from drug & device makers

$728,719in general payments, 2019–2025

Across 1,056 payments — averaging $690.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240K
  • Johnson & Johnson Surgical Vision, Inc.$211K
  • Tarsus Pharmaceuticals, Inc.$105K
  • Oyster Point Pharma, Inc.$65K
  • Bausch & Lomb Americas Inc.$51K
  • Alcon$35K
  • plus $21K from 25 others

What the payments were for

  • Consulting fees$260,51436%
  • Speaking & faculty fees$389,74053%
  • Travel & lodging$51,3607%
  • Food & beverage$27,0604%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$728,719 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$572,171
Medicare patients
1,088
Services billed
3,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$69,941
XdemvyLotilaner35$63,363
XiidraLifitegrast34$46,587
MieboPerfluorohexyloctane/Pf32$29,200
Cyclosporine34$28,415
TyrvayaVarenicline Tartrate31$21,540
LumiganBimatoprost38$20,916
Prednisolone Acetate275$11,170
ProlensaBromfenac Sodium21$6,921
ZirganGanciclovir13$5,764
Loteprednol Etabonate29$5,487
TafluprostTafluprost/Pf12$5,300
Dorzolamide-TimololDorzolamide/Timolol/Pf28$5,200
ValacyclovirValacyclovir Hcl60$3,352
FlarexFluorometholone Acetate25$3,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$239,964$90,85795 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan$51,273$81,55179 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$104,564$63,36335 claims
Oyster Point Pharma, Inc.Tyrvaya$65,223$21,54031 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$172$12,40950 claims
Eyevance Pharmaceuticals LLCFlarex$25$3,16125 claims
AlconSimbrinza$35,406$2,70113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Eatontown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →